53 related articles for article (PubMed ID: 33247397)
1. Effects of CYP2D6 genetic polymorphism on the pharmacokinetics of metoclopramide.
Bae JW; Oh KY; Yoon SJ; Shin HB; Jung EH; Cho CK; Lim CW; Kang P; Choi CI; Jang CG; Lee SY; Lee YJ
Arch Pharm Res; 2020 Nov; 43(11):1207-1213. PubMed ID: 33247397
[TBL] [Abstract][Full Text] [Related]
2. Effects of CYP2D6 *10 and *41 Variants in Healthy Chinese Men on the Pharmacokinetics of Dapoxetine.
Wang Z; Gao Y; Ji X; Wu T; Pu L; Qiu W
J Clin Pharmacol; 2024 May; 64(5):601-608. PubMed ID: 38059315
[TBL] [Abstract][Full Text] [Related]
3. Clinical implementation of pharmacogenomics: overcoming genetic exceptionalism.
Relling MV; Altman RB; Goetz MP; Evans WE
Lancet Oncol; 2010 Jun; 11(6):507-9. PubMed ID: 20413348
[No Abstract] [Full Text] [Related]
4. Should we stop prescribing metoclopramide as a prokinetic drug in critically ill patients?
van der Meer YG; Venhuizen WA; Heyland DK; van Zanten AR
Crit Care; 2014 Sep; 18(5):502. PubMed ID: 25672546
[TBL] [Abstract][Full Text] [Related]
5. ABCB1 c.2677G>T/c.3435C>T diplotype increases the early-phase oral absorption of losartan.
Shin HB; Jung EH; Kang P; Lim CW; Oh KY; Cho CK; Lee YJ; Choi CI; Jang CG; Lee SY; Bae JW
Arch Pharm Res; 2020 Nov; 43(11):1187-1196. PubMed ID: 33249530
[TBL] [Abstract][Full Text] [Related]
6. Plasma Trough Concentrations of Antihypertensive Drugs for the Assessment of Treatment Adherence: A Meta-Analysis.
Groenland EH; van Kleef MEAM; Bots ML; Visseren FLJ; van der Elst KCM; Spiering W
Hypertension; 2021 Jan; 77(1):85-93. PubMed ID: 33249865
[TBL] [Abstract][Full Text] [Related]
7. Physiologically based pharmacokinetic (PBPK) modeling for prediction of celecoxib pharmacokinetics according to CYP2C9 genetic polymorphism.
Kim YH; Kang P; Cho CK; Jung EH; Park HJ; Lee YJ; Bae JW; Jang CG; Lee SY
Arch Pharm Res; 2021 Jul; 44(7):713-724. PubMed ID: 34304363
[TBL] [Abstract][Full Text] [Related]
8. Distribution of
Abudukeremu M; Ayoufu A; Tuerhong A; Paizula X; Ou JH
Open Life Sci; 2024; 19(1):20220728. PubMed ID: 38681733
[TBL] [Abstract][Full Text] [Related]
9. PBPK modeling to predict the pharmacokinetics of venlafaxine and its active metabolite in different CYP2D6 genotypes and drug-drug interactions with clarithromycin and paroxetine.
Cho CK; Kang P; Jang CG; Lee SY; Lee YJ; Bae JW; Choi CI
Arch Pharm Res; 2024 May; 47(5):481-504. PubMed ID: 38664354
[TBL] [Abstract][Full Text] [Related]
10. An Unusual Case of an Acute Episode of Restless Leg Syndrome Following Oral Metoclopramide Therapy.
Aljunaid MA
Cureus; 2024 Feb; 16(2):e53754. PubMed ID: 38327722
[TBL] [Abstract][Full Text] [Related]
11. Physiologically based pharmacokinetic (PBPK) modeling of pitavastatin in relation to SLCO1B1 genetic polymorphism.
Cho CK; Mo JY; Ko E; Kang P; Jang CG; Lee SY; Lee YJ; Bae JW; Choi CI
Arch Pharm Res; 2024 Feb; 47(2):95-110. PubMed ID: 38159179
[TBL] [Abstract][Full Text] [Related]
12. PBPK modeling to predict the pharmacokinetics of pantoprazole in different CYP2C19 genotypes.
Cho CK; Ko E; Mo JY; Kang P; Jang CG; Lee SY; Lee YJ; Bae JW; Choi CI
Arch Pharm Res; 2024 Jan; 47(1):82-94. PubMed ID: 38150171
[TBL] [Abstract][Full Text] [Related]
13. Physiologically based pharmacokinetic (PBPK) modeling to predict the pharmacokinetics of irbesartan in different CYP2C9 genotypes.
Cho CK; Kang P; Jang CG; Lee SY; Lee YJ; Choi CI
Arch Pharm Res; 2023 Dec; 46(11-12):939-953. PubMed ID: 38064121
[TBL] [Abstract][Full Text] [Related]
14. Effects of CYP2D6 and CYP2C19 genetic polymorphisms and cigarette smoking on the pharmacokinetics of tolperisone.
Byeon JY; Cho CK; Kang P; Kim SH; Jang CG; Lee SY; Lee YJ
Arch Pharm Res; 2023 Aug; 46(8):713-721. PubMed ID: 37728834
[TBL] [Abstract][Full Text] [Related]
15. Case report: metoclopramide induced acute dystonic reaction in adolescent CYP2D6 poor metabolizers.
Fink FM; Bognar M; Hengl P; Paulmichl M; Nofziger C
Front Pharmacol; 2023; 14():1201566. PubMed ID: 37497103
[TBL] [Abstract][Full Text] [Related]
16. Diltiazem efficacy and CYP2D6 gene polymorphism in patients with atrial fibrillation with rapid ventricular response.
Uluturk M; Yilmaz A; Seyit M; Ozen M; Oskay A; Kemanci A; Unal M; Senol H; Koseler A; Turkcuer I
Egypt Heart J; 2023 Jun; 75(1):50. PubMed ID: 37326775
[TBL] [Abstract][Full Text] [Related]
17. Effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide in healthy subjects.
Kang P; Cho CK; Jang CG; Lee SY; Lee YJ; Choi CI; Bae JW
Arch Pharm Res; 2023 May; 46(5):438-447. PubMed ID: 37097441
[TBL] [Abstract][Full Text] [Related]
18. Impact of Cytochrome Induction or Inhibition on the Plasma and Brain Kinetics of [
Breuil L; Ziani N; Leterrier S; Hugon G; Caillé F; Bouilleret V; Truillet C; Goislard M; El Biali M; Bauer M; Langer O; Goutal S; Tournier N
Pharmaceutics; 2022 Nov; 14(12):. PubMed ID: 36559144
[TBL] [Abstract][Full Text] [Related]
19. Physiologically based pharmacokinetic (PBPK) modeling of flurbiprofen in different CYP2C9 genotypes.
Whang SS; Cho CK; Jung EH; Kang P; Park HJ; Lee YJ; Choi CI; Bae JW; Kim HS; Jang CG; Lee SY
Arch Pharm Res; 2022 Aug; 45(8):584-595. PubMed ID: 36028591
[TBL] [Abstract][Full Text] [Related]
20. Physiologically based pharmacokinetic modelling to predict the pharmacokinetics of metoprolol in different CYP2D6 genotypes.
Lee CM; Kang P; Cho CK; Park HJ; Lee YJ; Bae JW; Choi CI; Kim HS; Jang CG; Lee SY
Arch Pharm Res; 2022 Jun; 45(6):433-445. PubMed ID: 35763157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
